ImmunoGen, Inc. IMGN
Set alert
As of Feb 9, 3:58 PM ET
52-week range unavailable
- Open
- 31.24
- Prev close
- 31.24
- Mkt cap
- 8.72B
- Vol
- 19.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.22
- High
- 31.25
- Forward P/E
- 86.75
- Beta
- 1.17
- Short ratio
- 3.78
- Inst. own
- 86.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 6, 2024
- 50-d avg
- 29.71
- 200-d avg
- 19.72
- 1y target
- 25.50
Key statistics
- Market cap
- 8.72B
- Enterprise value
- 7.79B
- Trailing P/E
- 0.00
- Forward P/E
- 86.75
- PEG ratio
- 0.00
- Price / sales
- 30.33
- Price / book
- 15.20
- EPS (TTM)
- -0.28
- Beta
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -25.56%
- Revenue (TTM)
- 287.61M
- Revenue growth
- 637.70%
- Free cash flow
- -133.20M
- Total cash
- 605.53M
- Total debt
- 84.33M
- Return on equity
- -19.88%
- Shares outstanding
- 279.35M
- Short % of float
- 7.40%
- 50-day average
- 29.71
- 200-day average
- 19.72
Analyst view
Consensus: buy
- Target (low)
- 16.00
- Target (mean)
- 25.50
- Target (high)
- 31.00
- Strong buy4
- Buy1
- Hold3
- Sell1
- Strong sell0
Next earnings
Mar 6, 2024
Expected Mar 6, 2024. Consensus EPS estimate 0.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 6, 2024 | Dec 1, 2023 | 0.13 | — | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.02 | — | — | — |
| Jul 31, 2023 | Jun 1, 2023 | -0.16 | — | — | — |
| Apr 28, 2023 | Mar 1, 2023 | -0.25 | — | — | — |
| Mar 1, 2023 | Dec 1, 2022 | -0.29 | — | — | — |
| Nov 4, 2022 | Sep 1, 2022 | -0.26 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2023 | Oppenheimer | init | — | Perform |
| Sep 12, 2023 | JP Morgan | up | Neutral | Overweight |
| Aug 28, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 1, 2023 | Barclays | main | Overweight | Overweight |
| Jul 31, 2023 | Canaccord Genuity | main | Buy | Buy |
| Jul 31, 2023 | BMO Capital | main | Outperform | Outperform |
About ImmunoGen, Inc.
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunogen.com
News
- Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
- AbbVie Cuts Its Guidance on ImmunoGen Deal
- AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
- AbbVie Completes Acquisition of ImmunoGen
- Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
- ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
- 7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
- Cramer names biopharma companies to watch as industry mergers start to pile up
Your note
Sign in to keep a note on IMGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARBUCKLE STUART A | Director | Stock Award(Grant) | Dec 28, 2023 | 5,381 |
| COEN STACY ANN | Officer | Sale | Feb 4, 2024 | 73,274 |
| ENYEDY MARK J | Chief Executive Officer | Sale | Feb 4, 2024 | 584,397 |
| GOLDBERG MARK ALAN | Director | Stock Award(Grant) | Dec 28, 2023 | 60,720 |
| LENTINI RENEE | Officer | Sale | Feb 4, 2024 | 14,723 |
| PETERSON KRISTINE | Director | Sale | Nov 29, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.40% | 20,904,986 | 394.48M | Jun 29, 2023 |
| Vanguard Group Inc | 8.40% | 20,899,026 | 394.36M | Jun 29, 2023 |
| Redmile Group, LLC | 7.12% | 17,730,417 | 334.57M | Jun 29, 2023 |
| Janus Henderson Group PLC | 6.23% | 15,499,788 | 292.48M | Jun 29, 2023 |
| Wellington Management Group, LLP | 3.92% | 9,752,899 | 184.04M | Jun 29, 2023 |
| Point72 Asset Management, L.P. | 3.50% | 8,712,142 | 164.40M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.25% | 8,078,738 | 152.45M | Jun 29, 2023 |
| iShares Russell 2000 ETF | 2.22% | 5,530,172 | 87.60M | Aug 30, 2023 |
| Janus Henderson Global Life Sciences Fund | 1.49% | 3,718,755 | 70.17M | Jun 29, 2023 |
| Vanguard Small-Cap Index Fund | 1.33% | 3,301,242 | 62.29M | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.30% | 3,232,709 | 61.00M | Jun 29, 2023 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.14% | 2,841,588 | 45.01M | Aug 30, 2023 |